The Story of Successful Drugs and Recent FDA-Approved Molecules
A topical collection in Pharmaceuticals (ISSN 1424-8247). This collection belongs to the section "Medicinal Chemistry".
Viewed by 143Editors
2. Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
Interests: medicinal chemistry; organic synthesis; heterocycles; P-glycoprotein; anticancer; antimicrobials; chiral drugs; marine natural products
Special Issues, Collections and Topics in MDPI journals
Interests: heterocycles; medicinal chemistry; green chemistry; microwave-induced synthesis
Special Issues, Collections and Topics in MDPI journals
Interests: radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide theranostics; targeted endoradiotherapy; noninvasive molecular imaging; PET; SPECT
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal chemistry; organic synthesis; parasitic diseases; orphan drugs
Special Issues, Collections and Topics in MDPI journals
Interests: autodisplay; assay development and inhibitor testing; whole cell biocatalysts for synthesis of drugs and building blocks; directed evolution of enzyme inhibitors and biocatalysts; biosensor development and diagnostic tools
Special Issues, Collections and Topics in MDPI journals
Interests: host defense antimicrobial peptides; structural bioinformatics; biomolecular NMR
Special Issues, Collections and Topics in MDPI journals
Topical Collection Information
Dear Colleagues,
Each year, the FDA approves dozens of novel small molecules and biological derivatives as new therapeutic compounds, thus demonstrating the vigor of the pharmaceutical industry and associated research groups. Small molecules are the most represented entities among the approvals, but there are also an increasing number of antibodies and oligonucleotides on the medical market. Interestingly, there is a growing interest in the development of orphan drugs and the treatment of orphan diseases and rare diseases.
We invite readers of this Topical Collection to explore a range of short but comprehensive and updated reviews on drugs attracting particular attention owing to their success and to their compounds being (recently) approved by the FDA.
Dr. Maria Emília De Sousa
Dr. Jean Jacques Vanden Eynde
Prof. Dr. Klaus Kopka
Dr. Annie Mayence
Prof. Dr. Joachim Jose
Prof. Dr. Guangshun Wang
Collection Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody
- aptamer
- oligonucleotide
- orphan disease
- orphan drug
- peptide
- small molecule
